Mechanisms · Mechanism of Action
NMDA Receptor Antagonism
Ibogaine is a non-competitive NMDA receptor antagonist — a mechanism it shares with ketamine, dextromethorphan, and memantine, with implications for tolerance reversal and dissociative experience.
Quick Answer
What is nmda receptor antagonism in ibogaine pharmacology?
Reviewed by Dr. Arellano, M.D. — May 2026
How ibogaine binds NMDA
The NMDA receptor is a glutamate-gated ion channel central to learning, memory, and synaptic plasticity. Ibogaine binds within the open channel pore — a non-competitive site shared with ketamine, dextromethorphan, memantine, and PCP.
Channel-pore antagonism only blocks NMDA receptors that are already open, which gives this class a use-dependent profile: more active circuits get more block.
Why NMDA matters for opioid tolerance
Chronic opioid exposure upregulates NMDA receptor signaling, which is one of the molecular adaptations that drives escalating tolerance and dependence.
Pre-clinical work (Popik et al. 1995; Glick et al. 1996) demonstrated that NMDA antagonists, including ibogaine, reverse this NMDA upregulation. This is one mechanistic explanation for why a single ibogaine flood dose produces tolerance reset rather than simple withdrawal substitution.
NMDA and the dissociative experience
The waking-dream quality of the ibogaine flood-dose experience overlaps phenomenologically with high-dose ketamine — both compounds antagonize NMDA at saturating concentrations.
However, the ibogaine experience is much longer (8-24 hours) and includes serotonergic and sigma-2 components that give it a distinct character from pure NMDA antagonists. Patients commonly describe autobiographical-memory replay and a panoramic life-review state that ketamine does not reliably produce.
Targets
- NMDA receptor
- Glutamatergic signaling
- Tolerance pathways
Citations & Reading
- Popik P, et al. (1995). Pharmacological Reviews, 47(2), 235-253.
- Glick SD, et al. (1996). NIDA Research Monograph, 173, 39-63.
- Mash DC, et al. (1995). Annals of the New York Academy of Sciences, 765, 245-265.
For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.
Related mechanisms
Mu-Opioid Receptor
Ibogaine and noribogaine interact with the mu-opioid receptor at low affinity — but the clinical effect on opioid withdrawal is multifactorial, not a simple substitute-and-taper.
Noribogaine — The Long-Tail Metabolite
Noribogaine is ibogaine's CYP2D6-formed metabolite — cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.
BDNF & GDNF Upregulation
Ibogaine and noribogaine upregulate brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), driving downstream neuroplasticity and dopaminergic repair.